Previous 10 | Next 10 |
Shares of Sorrento Therapeutics (NASDAQ: SRNE) were jumping 11.2% higher as of 11:09 a.m. EST on Wednesday. The nice gain came after the company announced that it's filing an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin an earl...
Sorrento Therapeutics ([[SRNE]] +5.7%) has filed an Investigational New Drug ((IND)) application with the FDA seeking sign-off on the commencement of clinical development of an intranasal formulation of STI-2099, dubbed COVI-DROPS, a neutralizing anti-SARS-CoV-2 antibody, for the potential ou...
IND filing today for STI-2099 (COVI-DROPS™) for a phase 1 safety and pharmacokinetic study in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of COVI-AMG™. Initial trial is expected to be followed by ...
Sorrento Therapeutics (NASDAQ: SRNE) isn't letting Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) grab all the headlines about the healthcare industry's battle against the coronavirus. On Monday, Sorrento announced it has submitted an Investigational New Drug (IND) a...
Shares of Sorrento Therapeutics (NASDAQ: SRNE) fell 37.8% in October according to data provided by S&P Global Market Intelligence . Shares peaked on Oct. 13 in anticipation of a research and development presentation to go over the company's vast array of potential COVID-19 p...
Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...
The FDA has signed-off investigational new drug application for Phase 1 study with Sorrento's ([[SRNE]] -13.5%) intravenous ((IV)) COVI-AMG (STI-2020) for the treatment of COVID-19 patients with mild symptoms and a separate study to evaluate safety and pharmacokinetics in ...
IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers. These initial trials are expected to be followed by pivotal trials with a goal of potentially receiving ...
Sorrento currently presents a wide multitude of candidate drugs to combat COVID-19. Due to this huge Covid-19 program, the share price has skyrocketed in recent months, although since the August peak the stock price has been deflating to reach around $7. The problem here is that t...
The stock market rewards patience. Parking your money in securities with solid prospects and a strong competitive advantage is a great strategy for yielding substantial results over longer periods of time. But for some stocks, doubling in value in just a year is a real possibility. Investor...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Fuse Medical Inc (FZMD) is expected to report for Q1 2024 PhoneX Holdings Inc (PXHI) is expected to report for Q1 2024 Avalon GloboCare Corp. (ALBT) is expected to report for Q1 2024 Ricoh Company Ltd ADR (RICOY) is expected to report for Q4 2024 Amplitech Group Inc. (AMPG) is exp...
Inpixon (INPXV) is expected to report for Q1 2024 Siebert Financial Corp. (SIEB) is expected to report for Q1 2024 Greenwave Technology Solutions Inc. (GWAV) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q1 2024 Gelesis Holdings, Inc. (...
Sorrento Therapeutics Inc. (SRNE) is expected to report for Q1 2023